Press Releases

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on June 14, 2024 to holders of Common Shares of record on May 31, 2024.

The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase... (continue reading...)

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of... (continue reading...)

CALGARY, Alberta, May 23, 2024 (GLOBE NEWSWIRE) -- Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased to announce its second quarter 2024 financial results. The Company’s interim financial statements and notes thereto and Management’s Discussion and Analysis for the three and six months ended March 31, 2024, are available under CPS’s SEDAR+ profile.

Highlights

The Company devoted its time and resources during the three-month... (continue reading...)

• Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax
• Other key posters further support the efficacy of REZLIDHIA® (olutasidenib) in elderly, transplant-eligible, and post-MPN patients with AML

SOUTH SAN FRANCISCO, Calif., May 23, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)... (continue reading...)

SAN DIEGO--(BUSINESS WIRE)-- Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced a poster presentation highlighting the ongoing Phase 1 study of IAM1363, a selective and brain-penetrant inhibitor of HER2 signaling for the treatment of HER2-driven cancers. The TIP (trials in progress) poster will be shared at the American Society for Clinical Oncology (ASCO) Annual... (continue reading...)